149377-19-5

Basic information

• Product Name: 1-BOC-4-P-HYDROXYPHENYLPIPERIDINE
• Synonyms: 1-BOC-4-P-HYDROXYPHENYLPIPERIDINE ;4-(4-Hydroxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester;1-Boc-4-Hydroxyphenylpiperidine;tert-butyl 4-(4-hydroxyphenyl)piperidine-1-carboxylate;1-Piperidinecarboxylic acid, 4-(4-hydroxyphenyl)-, 1,1-dimethylethyl ester;1-Boc-4-P-Hydroxyphe
• CAS NO: 149377-19-5
• Molecular Formula: C₁₆H₂₃NO₃
• Molecular Weight: 277.35872
• Mol File: 149377-19-5.mol

Chemical Properties

• Boiling Point: 407.3°Cat760mmHg
• Flash Point: 200.1°C
• Appearance: /
• Density: 1.121g/cm³
• Vapor Pressure: 3.24E-07mmHg at 25°C
• Refractive Index: 1.541
• Storage Temp.: 2-8°C
• PKA: 10.15±0.30(Predicted)
• CAS DataBase Reference: 1-BOC-4-P-HYDROXYPHENYLPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-P-HYDROXYPHENYLPIPERIDINE(149377-19-5)
• EPA Substance Registry System: 1-BOC-4-P-HYDROXYPHENYLPIPERIDINE(149377-19-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 149377-19-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-BOC-4-P-HYDROXYPHENYLPIPERIDINE is used as a key intermediate for the synthesis of various compounds due to its ability to serve as a building block for the creation of biologically active molecules.
Used in Medicinal Chemistry Research:
1-BOC-4-P-HYDROXYPHENYLPIPERIDINE is used as a research compound for the development of new pharmaceuticals, leveraging its protected hydroxyl group and the BOC group's protective properties to enable selective reactions and functionalization in the synthesis process.
Used in the Synthesis of Potential Drug Candidates:
1-BOC-4-P-HYDROXYPHENYLPIPERIDINE is utilized as a precursor in the synthesis of potential drug candidates, contributing to the advancement of novel therapeutic agents for various medical conditions.

InChI:InChI=1/C16H23NO3/c1-16(2,3)20-15(19)17-10-8-13(9-11-17)12-4-6-14(18)7-5-12/h4-7,13,18H,8-11H2,1-3H3

Upstream product

• 62614-84-0 4-(4-hydroxyphenyl)-1,2,3,6-tetrahydropiperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 286961-24-8 benzyl 1,2,3,6-tetrahydro-4-(trifluoromethylsulphonyloxy)-pyridine-1-carboxylate 
• 1166820-03-6 benzyl 4-(4-hydroxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylate 
• 541-16-2 t-butyl malonate 
• 1869912-48-0 4-(piperidine-4-yl)phenol hydrobromide 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 1048970-17-7 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)piperidine-1-carboxylic acid tert-butyl ester 
• 6793-92-6 p-benzyloxyphenylbromide 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 106-41-2 4-bromo-phenol 
• 742067-11-4 4-(4-hydroxyphenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

BRAF DEGRADERS

Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.

BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY

Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand that binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD

The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.

CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE

The present invention provides novel compounds having the general formula (I) wherein R1 to R6, and m are as described herein, compositions including the compounds and methods of using the compounds.

SSAO INHIBITORS AND USES THEREOF

Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating or preventing a liver disease or condition.

MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Enantiospecific sp2–sp3 Coupling of ortho- and para-Phenols with Secondary and Tertiary Boronic Esters

The coupling of ortho- and para-phenols with secondary and tertiary boronic esters has been explored. In the case of para-substituted phenols, after reaction of a dilithio phenolate species with a boronic ester, treatment with Ph3BiF2 or Martin's sulfurane gave the coupled product with complete enantiospecificity. The methodology was applied to the synthesis of the broad spectrum antibacterial natural product (?)-4-(1,5-dimethylhex-4-enyl)-2-methyl phenol. For ortho-substituted phenols, initial incorporation of a benzotriazole on the phenol oxygen atom was required. Subsequent ortho-lithiation and borylation gave the coupled product, again with complete stereospecificity.

Practical synthesis of pharmaceutically relevant molecules enriched in sp3 character

The expedient synthesis of compounds enriched in sp3 character is key goal in modern drug discovery. Herein, we report how a single pot Suzuki-Miyaura-hydrogenation can be used to furnish lead and fragment-like products in good to excellent yields. The approach has been successfully applied in formats amenable to parallel synthesis, in an asymmetric sense, and in the preparation of molecules with annotated biological activity.

Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)

Here we report the discovery and optimization of a series of bivalent bromodomain and extraterminal inhibitors. Starting with the observation of BRD4 activity of compounds from a previous program, the compounds were optimized for BRD4 potency and physical

[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES

The invention concerns compounds of Formula (I) (Formula (I)) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined herein before in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.